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Abstract
Background
Encephalitis is parenchymal brain inflammation due to infectious or immune-mediated pro-
cesses. However, in 15–60% the cause remains unknown. This study aimed to determine if
the cytokine/chemokine-mediated host response can distinguish infectious from immune-
mediated cases, and whether this may give a clue to aetiology in those of unknown cause.
Methods
Wemeasured 38 mediators in serum and cerebrospinal fluid (CSF) of patients from the
Health Protection Agency Encephalitis Study. Of serum from 78 patients, 38 had infectious,
20 immune-mediated, and 20 unknown aetiology. Of CSF from 37 patients, 20 had infec-
tious, nine immune-mediated and eight unknown aetiology.
Results
Heat-map analysis of CSF mediator interactions was different for infectious and immune-
mediated cases, and that of the unknown aetiology group was similar to the infectious pat-
tern. Higher myeloperoxidase (MPO) concentrations were found in infectious than immune-
mediated cases, in serum and CSF (p = 0.01 and p = 0.006). Serum MPO was also higher
in unknown than immune-mediated cases (p = 0.03). Multivariate analysis selected serum
MPO; classifying 31 (91%) as infectious (p = 0.008) and 17 (85%) as unknown (p = 0.009)
as opposed to immune-mediated. CSF data also selected MPO classifying 11 (85%) as
infectious as opposed to immune-mediated (p = 0.036). CSF neutrophils were detected in
eight (62%) infective and one (14%) immune-mediated cases (p = 0.004); CSF MPO corre-
lated with neutrophils (p<0.0001).
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Conclusions
Mediator profiles of infectious aetiology differed from immune-mediated encephalitis; and
those of unknown cause were similar to infectious cases, raising the hypothesis of a possible
undiagnosed infectious cause. Particularly, neutrophils and MPOmerit further investigation.
Introduction
Encephalitis is a neurological emergency, which presents as headache, cognitive and beha-
vioural disturbance, sometimes with focal neurological signs; many cases progress to seizures,
coma and death [1]. The most common aetiologies are infectious, typically viruses, or
immune-mediated processes, which are often associated with specific antibodies [2,3]. Whilst
there may be overlap in the clinical presentations of these different aetiologies, early distinction
is critical, as specific antiviral or immunosuppressive treatment is required depending on the
cause [1,4]. Moreover, delays in starting this specific treatment are associated with increased
morbidity and mortality [5–8]. For example, in the most common sporadic viral encephalitis,
that due to herpes simplex virus (HSV), 70% of patients die without treatment, and this is
reduced to 10–30% with early aciclovir [6,9]. Despite the increasing recognition of immune-
mediated causes of encephalitis, the aetiology of encephalitis remains unknown in 15–60% in
most studies [10].
There is mounting evidence that the host inflammatory response, driven by cytokines, che-
mokines and associated mediators, may play a pivotal role in the pathogenesis of encephalitis
[11–14], and that some may represent biomarkers of subtypes of disease within a given aetiology
[15,16]. Indeed mediator profiles have been found to differ between aetiologies in other diseases
of central nervous system (CNS) inflammation [17,18]. However, whether these profiles differ
between infectious and immune-mediated encephalitis has not been established [19].
Earlier work has demonstrated the importance of considering the significance of any identi-
fied mediators in the pathogenesis of disease in the context of leucocyte subsets within the CNS
[20]. The early influx of neutrophils and subsequent necrosis recognised in HSV encephalitis is
not reported in immune-mediated cases, suggesting that there may be some significant differ-
ences, perhaps for mediators associated with neutrophil chemotaxis or degranulation, such as
myeloperoxidase (MPO) [21,22]. An improved understanding of the pathophysiology of
inflammation in encephalitis may have implications for optimising diagnostic tests and guiding
the use of adjunctive immune-modulatory therapies, such as those used in other neurological
inflammatory diseases [23,24].
Therefore, we conducted a study to examine the mediator profiles in the cerebrospinal fluid
(CSF) and serum of patients with acute encephalitis to address two questions. Firstly, does the
mediator profile differ between those of infectious and immune-mediated aetiologies; and sec-
ondly might characteristic mediator profiles suggest whether those of unknown aetiology are
more likely to be infectious or immune-mediated.
Materials and Methods
Patients
We analysed samples available from adult patients in a previous prospective clinical and diag-
nostic study- the Health Protection Agency (now Public Health England) Aetiological Study of
Encephalitis in England; this recruited 203 patients from 24 centres which each recruited over
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2 years (2005–2008); methods have been described in detail [2]. In brief, the case definition
included any person, of any age admitted to hospital with encephalopathy (altered conscious-
ness that persisted for>24 hours, including lethargy, irritability, or a change in personality and
behaviour) and with2 of: fever or history of fever (38°C); seizures and/or focal neurological
findings (with evidence of brain parenchyma involvement); CSF pleocytosis (>4cells/μL); and
electroencephalographic findings or neuroimaging suggestive of encephalitis. All patients
underwent an extensive panel of routine clinical and additional CSF testing for RNA, DNA
and antibodies to establish the aetiology. The investigations were guided by immune status,
travel history and, when no aetiology was established, further second-line testing as directed by
an expert panel review (Tables 1 and 2). Patients were catagorised into aetiological groups as
‘Infectious’ if a causal pathogen was identified, as ‘Immune-mediated’ if a causal antibody was
identified or they met the study definition for demyelinating illness, including acute dissemi-
nated encephalomyelitis (ADEM), and as ‘Unknown’ if they did not meet either of these
groups. Serum and CSF samples from patients in the cohort were used for this study if, after all
the diagnostic tests had been completed and an archived aliquot stored,>50υL was available
for testing.
Table 1. First line testing for all patients with encephalitis recruited through the prospective HPA Study of the Aetiology of Encephalitis in
England*.
Sub-group Investigation
If immunocompetent Routine CSF PCR:
Herpes simplex virus 1/2
Varicella zoster virus
Enterovirus
Parechovirus
Adenovirus
Human herpesvirus 6/7 (<30 years)
Consider other tests depending on clinical features†
Routine serology:
Mumps or measles
Inﬂuenza A or B
If immunocompromised CSF PCR As for immunocompetent, and consider:
Cytomegalovirus
Epstein-Barr virus
Human herpesvirus-6/7
JC virus
Lymphocytic choriomeningitis virus
JC virus
HIV Serology
If travelled abroad CSF PCR As for immunocompetent, and consider:
Arboviruses (Japanese encephalitis, dengue, tick-borne encephalitis, Murray Valley encephalitis, St Louis encephalitis)
Nipah virus
Poliomyelitis
Rabies
West Nile virus
*Algorithm assumes appropriate investigations were also done when clinically indicated to exclude bacterial, fungal, and parasitic infections.
†For cervical lymphadenopathy consider cytomegalovirus and Epstein-Barr virus; for respiratory illness consider inﬂuenza A and B; for parotitis and
orchitis consider mumps.
doi:10.1371/journal.pone.0146288.t001
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Patients provided written informed consent, the procedure for which was approved in the
HPA study by the North and East Devon Multicentre Research Ethics Committee (Reference:
05/Q2102/22). This sub-study was approved by the HPA Encephalitis Study Steering Group and
also by the Pan-Manchester Research and Development Group for the University of Manchester
Measurement of mediators
Serum and CSF samples were collected at recruitment and stored at -80°C. Thirty mediators
(cytokines, chemokines and associated mediators) were assessed using cytometric bead array
(Procarta Affymetrix Italy). A further panel for eight matrix metalloproteinases was performed
using the same technique where additional volumes were available. Mediators were identified
from previous literature and chosen to reflect, in part:
• Leucocyte proliferation and differentiation (granulocyte-colony stimulating factor [G-CSF],
granulocyte-macrophage-colony stimulating factor [GM-CSF], granzyme B, myeloperoxi-
dase, leptin and eSelectin);
• Leucocyte chemotaxis (CCL2 [monocyte chemotactant protein 1], CCL3 [monocyte inflam-
matory protein 1α], CCL5 [regulated on activation normal T cell expressed and secreted],
CXCL9, CXCL10 [inducible protein 10]);
• Adhesion molecules (vascular cell adhesion molecule [VCAM], intracellular adhesion mole-
cule [ICAM]);
• Markers of BBB permeability (vascular endothelial growth factor [VEGF]α, and matrix
metalloproteinases [MMP] 1,2,3,7,8,9,12, and 13);
• Antiviral and related peptides (interferon [IFN] α,β,o,γ tumour necrosis factor [TNF]α and
its soluble receptors [TNFR1 and TNFR2] and TNFα-related apoptosis inducing ligand
[TRAIL]);
• Broadly pro-inflammatory interleukins (IL-1α, 1β, 6, 8, and 17α); and
• Broadly anti-inflammatory interleukins (IL1-receptor antagonist [IL1RA], IL-4, and IL-10).
Fluorescence intensity was determined using a Bio-Rad platform (BioPlex Manager 4.1, Bio-
Rad, UK). Standards and samples were analysed in duplicate and mean value used. Standard
curves were adjusted at the points of fluorescence intensity saturation, generating a sigmoid
curve with 6–8 fluorescence points, as described [17]. To avoid undetectable levels or missing
data bias, only mediators detected in>80% were included in analyses, as described [11].
Table 2. Additional pathogens investigated in patients in whom panel 1 testing was negative as deter-
mined by the expert review panel for the HPA Study of the Aetiology of Encephalitis in England.
Group Pathogen
Viral Cytomegalovirus, Epstein-Barr virus, ﬂaviviruses, hepatitis viruses, human T-cell lymphotropic
virus, lymphocytic choriomeningitis virus, parainﬂuenza virus, parvovirus B19, poliovirus,
rabies virus, respiratory syncytial virus
Bacterial Bacillus anthracis, Bartonella henselae, Chlamydophila psittaci, Chlamydia trachomatis,
Legionella pneumophila, Leptospira spp, Listeria monocytogenes, Borrelia burgdorferi,
Mycoplasma pneumoniae, Mycobacterium tuberculosis, Salmonella spp, Streptococcus
pneumoniae, Streptococcus pyogenes
Rickettsial Coxiella burnetii, Rickettsia rickettsia
Parasitic Toxoplasma gondii
Fungal Histoplasma capsulatum
doi:10.1371/journal.pone.0146288.t002
Cytokine Profiles in Encephalitis of Infectious, Immune-Mediated, and Unknown Cause
PLOS ONE | DOI:10.1371/journal.pone.0146288 January 25, 2016 4 / 19
Statistics
Freeze/thaw cycles were minimised, typically to 2–3, in the central laboratory. Nevertheless, to
minimise any potential impact of any possible variation in sample storage, concentrations were
median-centred and normalised for each patient, using established methodology [11,17].
Therefore, the concentration of each mediator was expressed and analysed as a value relative to
the median concentration of all of the mediators in that patient sample [11,17]. These median-
centered concentrations of each mediator were compared for statistically significant differences
between the aetiological groups rather than comparing against normative data, as it was the
power of mediators to distinguish between the causes of encephalitis that was the focus of this
paper. Overall mediator data for all aetiologies underwent a one-way hierarchical cluster analy-
sis. Then mediator data from each aetiological group underwent nearest neighbour analysis,
using Pearson’s correlation coefficient, to generate proximity matrices (representing the
strength of correlation between mediators)(SPSS 2011); from these, heat-maps were generated
(SigmaPlot, Systat Software,USA), as described [17,25]. This generates a visual representation
of the interaction of all mediators with each other in each aetiological group.
The Mann-Whitney U test was used for categorical variables and Kendall’s rank for contin-
uous variables (SPSS 2011). Step-wise discriminant function analysis was used to develop a
multivariate model, which underwent a leave-one-out cross-validation to protect against type 1
error; the power of each mediator is expressed using Wilk’s Lambda coefficient, from perfect
discriminatory power (0.0) to none (1.0). This assisted by generating a model based not just on
absolute concentrations of selected mediator(s), but also with a numerical weighting applied to
selected mediator(s). This was generated using data from the majority of patients and tested on
a random subset in a split-reliability analysis. Significance was defined as p<0.05.
Results
Patient cohort
A total of 95 patients were identified, 78 of whom had serum samples of sufficient volume
available; these comprised 38 with an infectious aetiology (17 HSV, 7 varicella zoster virus
[VZV], 5 tuberculosis, 3 bacterial, 2 dual infection (1 TB and HIV; 1 cryptococcus and VZV), 1
influenza A, 1 measles, 1 HIV, 1 toxoplasmosis); 20 immune-mediated cases (9 antibody-medi-
ated, 8 ADEM, 1 paraneoplastic, 1 vasculitis, 1 multiple sclerosis), and 20 of unknown aetiol-
ogy. For 37 patients CSF samples of sufficient volume were available, 19 with an infectious
aetiology (11 HSV, 6 VZV, 1 JC virus, and 1 toxoplasmosis), 9 immune-mediated (5 ADEM, 3
antibody-mediated, 1 paraneoplastic), and 8 of unknown aetiology. Additional samples were
available to assess the MMP panel for 62 serum and 18 CSF samples.
Comparison between intrathecal and vascular compartments
The following mediators were not identified in>80% of the cohort and were therefore
removed from further analysis: TNFR1 and 2, eSelectin, CXCL9, IL-17α, and VEGFα.
The mediators that tended to be found at higher concentrations in either the CSF or the
serum were similar across all the aetiological groups (Fig 1). Significantly higher relative con-
centrations of several mediators, including IL-1α, IL-1β, IL-10, and CCL-2, were seen in the
CSF than the serum for all aetiological groups. Also, for the infectious and unknown groups,
higher concentrations of IL-4 and leptin occurred in the CSF than the serum. For the cohort
overall the only mediators which showed a positive correlation between concentrations in the
CSF and serum were MPO (tau b [95%CI] 0.42 [0.11–0.74], p = 0.009), CXCL-10 (0.43 [0.18–
0.68], p = 0.01), and IL-4 (0.31 [0.01–0.61], p = 0.04).
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Univariate analysis of mediator profiles for different aetiological groups
Univariate analysis of mediator concentrations showed many similarities but also several dif-
ferences between the aetiological groups (Tables 3 and 4). The predominant differences were
between the infectious and immune-mediated groups and also between the unknown and the
immune-mediated group. No significant differences were found between the infectious and
unknown groups in either the CSF or the serum.
In particular, higher concentrations of MPO were identified in both the serum and CSF of
patients with infectious than immune-mediated aetiologies (p = 0.01 and p = 0.006 respec-
tively) (Figs 2 and 3). Interestingly, the serum MPO concentration was also higher in those
with unknown aetiology than immune-mediated disease (p = 0.03). In addition, median CSF
concentrations for several of the mediators were similar for the infectious and unknown
groups, but differed for the immune-mediated group: specifically, higher median concentra-
tions of IL-8 were seen in both infectious and unknown cases as opposed to those that were
immune-mediated; in contrast higher median concentrations of IL-4 were found in those with
immune-mediated disease than either of the other groups. To assess whether the predominant
infectious aetiology, which was the HSV group, had a similar mediator pattern to that seen in
the rest of the infectious group the two were compared (Table 5). There were no statistically
significant differences for any of the mediators assessed in CSF between those with HSV and
Fig 1. Concentrations of mediators in the CSF and serum of patients with encephalitis of immune-mediated, infectious and unknown aetiologies.
doi:10.1371/journal.pone.0146288.g001
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the rest of the group with an infectious aetiology. In serum there were also no significant differ-
ences between the two groups other than for IL-1α and ICAM. However, IL-1α did not differ
significantly different between infectious and other aetiological groups overall, although ICAM
approached significance.
Heatmaps of mediator profiles for different aetiological groups
Hierarchical cluster analysis of mediators from all patients identified two broad clusters of
mediators, which were used in the heat-maps. The first cluster of serum mediators contained
IL-1α, IL-1β and IL-10, in addition to other mediators; in CSF these same mediators were clus-
tered together with the addition of IL-1RA. The second cluster in serum contained several
mediators including IFNα, IFNβ, IFNγ and IFNo; these same mediators clustered together in
CSF. Heat-maps derived from serum mediator concentrations showed strong positive correla-
tions between mediators in the first cluster and strong negative correlation in between media-
tors in the second cluster in all aetiological groups and this did not appear to be substantially
different between groups (Fig 4). However, heat-maps derived from CSF mediator concentra-
tions appeared to demonstrate strong positive correlations between the first cluster of media-
tors in the infectious group that was not present in those with immune-mediated aetiology. To
Table 3. Median concentrations of identified mediators between the aetiological groups of encephalitis in serum.
Aetiological Group P value
Mediator Immune-mediated Infectious Unknown IMM vs INF IMM vs UNK INF vs UK
CCL2 0.041 [-0.560 to 0.652] 0.042 [-0.726 to 0.664] 0.040 [-0.791 to 1.041] 0.64 0.99 0.59
CCL3 -0.548 [-1.343 to 0] -0.526 [-1.487 to -0.047] -0.473 [-1.059 to -0.053] 0.62 0.99 0.71
CCL5 1.390 [-0.986 to 2.694] 2.129 [-0.849 to 2.966] 2.057 [-0.801 to 2.669] 0.15 0.50 0.35
CXCL10 0.400 [0.030 to 1.868] 0.728 [-0.038 to 1.778] 0.429 [-0.320 to 1.720] 0.17 0.83 0.08
G CSF -0.153 [-1.291 to 0.771] -0.283 [-1.151 to 0.451] -0.710 [-1.112 to 0.054] 0.50 0.23 0.55
GM CSF 0.056 [-1.125 to 0.258] -0.372 [-1.359 to 0.540] -0.446 [-1.393 to 0.396] 0.10 0.42 0.26
Granzyme B -0.222 [-1/049 to 0.298] -0.187 [-1.141 to 0.064] -0.488 [-1.382 to 0.176] 0.49 0.05 0.24
IFNβ -0.747 [-2.552 to 0.061] -0.213 [-2.502 to 0.126] -0.897 [-2.427 to 0.277] 0.25 0.94 0.24
IFNγ -0.814 [-1.660 to -0.349] -0.860 [-1.601 to 0.180] -0.914 [-1.158 to -0.467] 0.53 0.28 0.80
IFNo -0.210 [-0.617 to 0.605] -0.306 [-0.770 to 0.413] -0.186 [-0.650 to 0.882] 0.36 0.99 0.37
ICAM 1.694 [-0.302 to 4.401] 2.007 [0.297 to 2.919] 1.976 [0.778 to 2.656] 0.05 0.18 0.72
IL-1α -0.640 [-1.925 to 0.058] -0.904 [-1.694 to 0.103] -1.271 [-1.652 to 0.112] 0.46 0.28 0.86
IL-1β -0.897 [-1.939 to -0.269] -1.005 [-2.342 to -0.073] -1.005 [-2.073 to -0.388] 0.39 0.27 0.89
IL-1RA 0.261 [-0.261 to 1.214] 0.159 [-0.107 to 1.609] 0.374 [-0.147 to 1.019] 0.94 0.30 0.15
IL-4 -0.321 [-1.387 to 0.007] -0.625 [-1.332 to 0.192] -0.812 [-1.274 to -0.161] 0.09 0.14 0.79
IL-6 -0.125 [-1.617 to -0.036] 0.070 [-1.469 to 0.421] -0.152 [-1.717 to 1.246] 0.25 0.87 0.46
IL-8 -1.127 [-2.468 to 2.207] -0.256 [-2.123 to 1.194] -0.782 [-1.892 to 0.480] 0.10 0.23 0.48
IL-10 -0.845 [-2.105 to 0.046] -0.957 [-2.446 to 0.160] -1.051 [-2.334 to -0.110] 0.36 0.55 0.53
Leptin 0.911 [0.013 to 2.041] 1.178 [-0.189 to 2.414] 0.914 [0.102 to 2.625] 0.82 0.94 0.74
MMP8 0.001 [-2.289 to 1.262] -0.100 [-2.089 to 1.464] -0.020 [-2.300 to 1.561] 0.43 0.87 0.40
MMP9 0.854 [-2.357 to 1.728] 0.905 [-2.455 to 4.747] 1.248 [-2.790 to 2.557] 0.98 0.19 0.20
MPO 0.687 [-0.301 to 2.276] 1.119 [-0.431 to 2.289] 1.026 [-0.040 to 2.158] 0.01 0.03 0.80
TNFα -0.589 [-1.636 to -0.215] -0.913 [-1.668 to -0.099] -0.993 [-1.610 to -0.138] 0.04 0.32 0.27
TRAIL 0.139 [-0.107 to 1.139] 0.274 [0 to 1.301] 0.224 [-0.077 to 1.210] 0.23 0.51 0.44
VCAM 1.728 [-0.435 to 2.383] 1.600 [-0.475 to 2.551] 1.854 [0.675 to 2.519] 0.85 0.11 0.19
Abbreviations: IMM Immune-mediated; INF Infectious; UNK Unknown aetiology. Values are median-centred as described and expressed as pg/mL.
doi:10.1371/journal.pone.0146288.t003
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assess whether the mediator heat-map from the unknown group better reflected the infectious
or immune-mediated group these were compared. The heat-maps of CSF mediators appeared
to be similar for the infectious and unknown groups and both appeared substantially different
from those with an immune-mediated aetiology.
Discriminant function analysis of mediator profiles for different
aetiological groups
To see which specific mediators might be used to distinguish between aetiological groups we
used discriminant function analysis for pairwise comparisons of the groups. For discriminant
function analysis of serum data this generated a model that used serumMPO alone to distin-
guish 31 (89%) of 35 samples as infective and five (31%) of 16 as immune-mediated (Wilks’
lambda 0.83, p = 0.008). This technique also generated a model using serumMPO alone to dis-
tinguish 17 (85%) of 20 samples of unknown aetiology and six (38%) of 16 immune-mediated
samples (0.78, p = 0.009); both were confirmed on the leave-one-out cross validation. No serum
variables qualified as distinguishing samples of infective versus unknown aetiology. A serum
MPO concentration cut-off of>0.8pg/mL correctly identified 27 (77%) infective, 17 (85%) as
unknown, and 8 (50%) immune-mediated cases; to assess the usefulness of this cut off value for
Table 4. Median concentrations of identified mediators between the aetiological groups of encephalitis in cerebrospinal fluid.
Aetiological Group p value
Mediator Immune-mediated Infectious Unknown IMM vs INF IMM vs UNK INF vs UK
CCL2 0.250 [-0.176 to 0.783] 0.459 [-0.755 to 0.683] 0.656 [-0.470 to 1.095] 0.41 0.83 0.13
CCL3 -0.289 [-0.407 to -0.136] -0.383 [-0.892 to -0.102] -0.413 [-0.660 to -0.236] 0.36 0.03 0.35
CCL5 -0.625 [-0.986 to 0.954] -0.439 [-1.144 to -0.165] -0.573 [-1.107 to 0.685] 0.61 0.64 0.66
CXCL10 0.242 [-0.50 to 1.729] 1.203 [-0.060 to 1.686] 0.986 [-0.068 to 1.561] 0.22 0.56 0.66
G CSF 0.148 [-0.269 to 2.360] 0.275 [-0.273 to 2.218] -0.091 [-0.423 to 2.091] 0.97 0.30 0.66
GM CSF 0.116 [-0.210 to 0.345] -0.059–0.627 to 0.011] -0.153 [-0.423 to 0.146] 0.01 0.28 0.66
Granzyme B -0.351 [-0.381 to 1.839] 0.216 [-0.495 to 1.620] -0.223 [-0.489 to 1.570] 0.55 0.91 0.56
IFNβ 0.202 [-0.167 to1.917] 1.935 [-0.427 to 2.266] 1.968 [-0.407 to 2.138] 0.22 0.11 0.37
IFNγ -0.857 [-1.042 to -0.590] -0.595 [-1.265 to 0.981] -0.721 [-1.317 to 1.185] 0.17 0.49 0.61
IFNo 0.109 [-0.697 to 0.289] -0.380 [-0.510 to 1.053] -0.476 [-0.785 to 1.256] 0.72 0.73 0.35
ICAM 1.465 [0.786 to 2.272] 1.437 [0.622 to 2.118] 1.243 [0.8502 to 2.003] 0.91 0.64 0.89
IL-1α -0.145 [-0.384 to 0.058] -0.211 [-1.046 to 0.015] -0.216 [-0.793 to -0.117] 0.72 0.17 0.13
IL-1β -0.452 [-0.581 to -0.245] -0.600 [-1.005 to -0.307] -0.602 [-0.801 to -0.467] 0.08 0.01 0.56
IL-1RA 0.097 [-0.010 to 0.158] 0.536 [-0.708 to 1.609] 0.134 [-0.504 to 1.096] 0.01 0.56 0.11
IL-4 -0.127 [-0.393 to 0.088] -0.291 [0.708 to -0.132] -0.339 [-0.569 to -0.247] 0.03 0.02 0.47
IL-6 -0.133 [-0.498 to 2.066] 0.661 [-0.334 to 1.924] 0.778 [0.001 to 1.797] 0.36 0.17 0.06
IL-8 -0.122 [-0.418 to 0.156] 0.318 [-0.553 to 1.319] 0.436 [-0.329 to 1.102] 0.04 0.03 0.61
IL-10 -0.508 [-0.855 to -0.384] -0.606 [-1.448 to 0.007] -0.721 [-1.244 to -0.569] 0.72 0.02 0.15
Leptin 0.653 [0.402 to 2.486] 1.960 [-0.007 to 2.344] 2.045 [0.407 to 2.216] 0.78 0.49 0.61
MMP8 0.300 [-3.423 to 1.581] -0.132 [-2.974 to 1.418] 1.198 [-3.276 to 4.094] 0.97 0.17 0.43
MMP9 1.031 [-4.132 to 2.484] -0.024 [-4.549 to 4.268] 1.207 [-3.374 to 2.873] 0.91 0.56 0.39
MPO 0.560 [0.210 to 0.927] 1.030 [0.060 to 1.944] 1.034 0.142 to 2.147] 0.01 0.30 0.47
TNFα -0.465 [-0.114 to -0.825] -0.588 [-1.574 to -0.131] -0.746 [-1.371 to -0.459] 0.25 0.11 0.52
TRAIL 0.046 [-0.155 to 0.298]] 0.139 [-0.339 to 1.537] 0.284 [-0.293 to 1.741] 0.17 0.06 0.17
VCAM 1.113 [-0.561 to 1.905] 1.121 [-1.170 to 2.192] 0.896 [-0.922 to 1.930] 0.84 0.54 0.83
Abbreviations: IMM Immune-mediated; INF Infectious; UNK Unknown aetiology. Values are median-centred as described and expressed as pg/mL.
doi:10.1371/journal.pone.0146288.t004
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Fig 2. Serum concentrations of mediators in patients with encephalitis of immune-mediated, infectious and unknown aetiology. Bars represent
median concentration.
doi:10.1371/journal.pone.0146288.g002
Cytokine Profiles in Encephalitis of Infectious, Immune-Mediated, and Unknown Cause
PLOS ONE | DOI:10.1371/journal.pone.0146288 January 25, 2016 9 / 19
Fig 3. CSF concentrations of mediators identified in patients with encephalitis of immune-mediated, infectious and unknown aetiology.
doi:10.1371/journal.pone.0146288.g003
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MPO this was then applied to samples from 7 patients (3 infective and 4 immune-mediated)
that had not been included in the initial analysis. In this split-reliability analysis all three cases
were identified as infective but none of the four were identified as immune-mediated.
Discriminant function analysis of CSF data generated a model which again used MPO alone
to correctly classify 11 (85%) of 13 cases as infective and four (67%) of six cases as immune-
mediated (0.77, p = 0.036); this was confirmed on the leave-one-out cross validation. A CSF
MPO concentration cut-off of 1.0pg/mL correctly classified nine (69%) infective cases and four
(67%) immune-mediated cases. The proportion of cases correctly classified was the same when
applied to the raw data using a cut-off of 1000pg/mL. To assess the usefulness of this cut off
value we assessed this in 9 patients (6 infective and 3 immune mediated) not included in the
original analysis. In this split-reliability analysis three of six and one of three cases were classi-
fied as infective or immune-mediated respectively.
As MPO is released during degranulation of neutrophils, we assessed whether these findings
may reflect the relative neutrophil concentration between the different aetiological groups.
Eight (62%) of the infective group had detectable neutrophils in the CSF, as opposed to only
Table 5. Comparison between the medianmediator concentrations in serum and CSF in patients with HSV encephalitis and the rest of the group
with encephalitis of an infectious aetiology.
Serum Cerebrospinal ﬂuid
Mediator HSV (n = 17) Non-HSV Infection (n = 21) p value HSV (n = 11) Non-HSV Infection (n = 7) p value
CCL2 0.100 [-0.646 to 0.412] 0.053 [-0.244 to 0.664] 0.65 0.413 [0.086 to 0.683] 0.243 [-0.755 to 0.664] 0.48
CCL3 -0.401 [-0.906 to -0.047] -0.561 [-0.688 to -0.072] 0.12 -0.345 [-0.537 to -0.130] -0.455 [-0.892 to -0.102] 0.43
CCL5 1.111 [-0.845 to 2.789] 2.037 [-0.849 to 2.966] 0.1 -0.364 [-1.144 to 0.453] -0.359 [-0.849 to 0.481] 0.98
CXCL10 0.801 [-0.38 to 1.723] 0.772 [0.095 to 1.778] 0.9 1.118 [-0.60 to 1.686] 1.240 [1.104 to 1.465] 0.65
G CSF -0.302 [-1.100 to 0.451] -0.526 [-1.126 to 0.135] 0.16 0.815 [-0.096 to 2.141] 0.813 [-0.273 to 2.218] 0.10
GM CSF -0.247 [-1.145 to 0.540] -0.484 [-1.263 to 0.359] 0.23 -0.065 [-0.272 to 2.218] -0.168 [-0.627 to 0.079] 0.37
Granzyme B -0.350 [-1.152 to 0.857] -0.437 [-1.821 to 0.310] 0.65 0.524 [-0.857 to 1.620] 0.117 [-0.495 to 1.366] 0.35
ICAM 1.870 [0.397 to 2.804] 2.305 [1.645 to 2.919] 0.03 1.402 [0.622 to 2.118] 1.625 [1.216 to 2.097 0.40
IFNα -0.159 [-0.313 to 0] -0.291 [-1.151 to 0.223] 0.64 0.013 [-1.128 to 1.837] 0.549 [-0.831 to 2.090] 0.39
IFNβ -0.562 [-1.892 to 0] -1.103 [-2.502 to 0.126] 0.12 1.441 [-0.364 to 2.117] 1.104 [-0.427 to 2.266] 0.62
IFNγ -0.153 [-0.695 to 0.413] -0.313 [-0.770 to 0.308] 0.18 -0.522 [-0.960 to 0.041] -0.249 [-1.265 to 0.981] 0.48
IFNo -0.824 [1.561 to -0.269] -0.760 [-1.601 to 0.180] 0.6 -0.340 [-0.569 to 0.413] 0.105 [-0.510 to 1.053] 0.14
IL-1α -0.584 [-1.596 to 0.103] -0.933 [-1.694 to -0.229] 0.04 -0.226 [-0.632 to 0.015] -0.280 [-1.046 to 0.005] 0.77
IL-1β -0.894 [-2.135 to -0.073] -1.241 [-2.342 to -0.270] 0.1 -0.559 [-0.748 to -0.402] -0.635 [-1.005 to -0.307] 0.53
IL-1RA 0.366 [-0.107 to 1.609] 0.425 [-0.092 to 0.985] 0.67 0.741 [-0.133 to 1.609] 0.339 [-0.708 to 1.321] 0.29
IL-4 -0.447 [-1.320 to 0.192] -0.692 [-1.332 to 0.038] 0.1 -0.320 [-0.493 to -0.165] -0.398 [-708 to -0.132] 0.45
IL-6 -0.115 [-0.728 to 0.254] -0.468 [-1.212 to 0.421] 0.11 0.723 [-0.068 to 1.847] 0.767 [-0.334 to 1.924] 0.93
IL-8 -0.335 [-2.123 to 1.194] -0.417 [1.433 to 0.186] 0.7 0.507 [-0.027 to 1.319] 0.160 [-0.553 to 1.003] 0.24
IL-10 -0.956 [-2.446 to 0.007] -1.062 [-2.408 to 0.160] 0.6 -0.428 [-0.870 to 0.007] -0.801 [-1.448 to -0.485] 0.09
Leptin 1.135 [-0.007 to 1.994] 1.154 [-0.189 to 2.414] 0.9 1.366 [-0.007 to 2.267] 1.361 [0.040 to 2.344] 0.99
MMP8 -0.398 [-2.089 to 0.754] -0.018 [-1.669 tp 1.464] 0.18 0.135 [-1.662 to 1.418] -1.450 [-2.974 to 0.626] 0.07
MMP9 1.124 [-2.455 to 4.747] 0.721 [-1.076 to 4.268] 0.45 -0.186 [-4.295 to 3.936] 0.111 [-4.549 to 4.268] 0.87
MPO 1.222 [0.305 to 2.216] 1.130 [-0.431 to 2.289] 0.6 1.032 [0.060 to 1.627] 1.196 [0.540 to 1.944] 0.57
TNFα -0.854 [-1.668 to -0.099] -1.006 [-1.609 to -0.320] 0.29 -0.650 [-0.795 to -0.499] -0.710 [-1.574 to -0.131] 0.76
TRAIL 0.358 [0.015 to 0.730] 0.323 [0 to 1.301] 0.7 0.096 [-0.339 to 0.493] 0.417 [0.088 to 1.537] 0.22
VCAM 1.291 [-0.435 to 2.303] 1.634 [-0.475 to 2.551] 0.2 1.189 [0.555 to 2.192] 0.956 [-1.170 to 2.092] 0.65
Values are median-centred as described and expressed as median [range] in pg/mL.
doi:10.1371/journal.pone.0146288.t005
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one (14%) of the immune-mediated group (p = 0.004). Moreover, across the whole cohort
there was a strong positive correlation between CSF neutrophil count and CSF MPO concen-
tration (tau b [95% CI] 0.70 [0.31–1], p<0.0001) (Fig 5). In the split reliability analysis neutro-
phils were detectable in the CSF for three of five infective samples and none of two immune-
mediated samples, for whom data were available. There were no significant differences in the
proportion of CSF samples with a detectable neutrophil count between the other aetiological
groups. There was no significant correlation between either the CSF or the serum
Fig 4. The heatmaps give a visual representation of how closely concentrations of different mediators correlate in the samples by nearest
neighbour correlation. Using a hierarchical cluster analysis the mediators are listed in the same order for each of the three aetiological groups to allow a
visual comparison of the pattern between the groups. In the serum (a) the pattern of mediator correlations is similar for all three aetiological groups, where-as
in the cerebrospinal fluid (b) the pattern differed between immune-mediated and infectious aetiologies, and the pattern for those of unknown aetiology is
closer to that seen with infection.
doi:10.1371/journal.pone.0146288.g004
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concentration of MPO and time from symptom-onset to sample collection. Discriminant anal-
ysis of CSF mediators identified eight (100%) of the unknown and five (83%) of immune-medi-
ated samples using IL-8 and CCL-3 (Wilks’ lambda 0.62, p = 0.018 and 0.21, p<0.0001
respectively). Discriminant function analysis was again not able to generate a model that could
distinguish CSF samples of an infective aetiology from samples of an unknown aetiology.
Discussion
This study has shown that the cytokine and associated mediator profiles in UK patients with
infectious encephalitis differ from those with immune-mediated aetiologies, particularly in the
CSF. For patients with unknown aetiology patterns in CSF most closely resembled infectious
cases, suggesting they may have undiagnosed infection. MPO was the mediator of greatest sig-
nificance, with higher concentrations in patients with infection, and CSF MPO concentration
was strongly correlated with CSF neutrophil count.
There are an estimated 0.07–12.6 cases of encephalitis per 100,000/year [1,2,10,26]. The
most common cause is infection and immune-mediated cases are being recognised increasingly
[2,27]. However, the aetiology remains unknown in 15–60% of cases, despite comprehensive
investigation [2,10,28]. There is mounting evidence that the host inflammatory process may
play an important role in the pathogenesis whatever the underlying aetiology [11–16]. These
mediators modulate both the innate and adaptive responses and regulate leucocyte infiltration
[29,30]. However, little is known about how the responses compare between encephalitis of dif-
ferent causes.
Fig 5. Cerebrospinal fluid myeloperoxidase concentration and cerebrospinal fluid neutrophil count for all cases of encephalitis. Because at low
levels neutrophils are just recorded as present or absent, and at higher levels actual counts are given we looked at CSF MPO concentrations using both
these parameters. CSF neutrophil counts were given for 11 patients.
doi:10.1371/journal.pone.0146288.g005
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Therefore, we analysed CSF and serum samples from 95 patients with encephalitis recruited
prospectively in the HPA Encephalitis Study [2]. We found that there were many similarities
across the aetiological groups. Particularly, mediators that were identified at higher concentra-
tions in the CSF than in the serum were similar between all aetiological groups; also those pres-
ent at higher concentrations in the serum were similar across all aetiological groups. In line
with a previous study of viral encephalitis we found higher relative levels of CCL-2 and IL-6 in
the CSF than serum and higher levels of CCL-5 in serum; in our study this was also found in
those with immune-mediated and unknown aetiologies [11]. However, several differences
between mediators, particularly in the CSF, were identified for the different aetiological groups.
Cluster analysis identified a group of mediators containing IL-1α, IL-1β, IL-1RA and IL-10,
which are all strongly associated with inflammation, whatever the cause [31]. CSF heat-maps
demonstrated that the pattern of mediator response for those with encephalitis of unknown
cause was similar to that for infectious rather than immune-mediated causes, suggesting they
may actually have infectious encephalitis, but the causative agent has not been identified.
Discriminant analysis of both CSF and serum identified MPO as the mediator that most
strongly discriminated cases of an infective or unknown aetiology from immune-mediated
cases. CSF concentrations of MPO correlated with CSF neutrophil count, suggesting that CSF
neutrophils may be the primary source of MPO identified. A higher percentage of patients had
detectable neutrophils in the CSF in the infectious as opposed to immune-mediated group,
although this was not as strong an association as the MPO concentration, perhaps suggesting
that the MPO in the CSF may also reflect neutrophil extracellular traps [32]; these are networks
of extracellular fibres produced by neutrophils, made up of DNA, MPO, and other proteins,
that bind microorganisms. Or the MPO detected may in part reflect neutrophils that were pre-
viously present in CSF and have migrated into the brain parenchyma or back into serum.
Neutrophils are known to be an important part of the host response early in viral encephali-
tis, before lymphocytes predominate; in bacterial central nervous system infections the neutro-
phil counts predominate, and are typically much higher. Interestingly, neutrophils have been
identified recently in murine models of HSV encephalitis, and may be important for reducing
viral load, albeit whilst also being associated with the production of, potentially neurotoxic,
reactive oxygen species [33–35]. Histopathological descriptions of clinical HSV encephalitis
have reported a predominance of neutrophils in the first 2–3 days [22]. Although after 10–15
days macrophages and lymphocytes are the predominant populations, the progressive necrosis
leads to further neutrophil infiltration, which would be supported by our findings [22]. Histo-
pathological data for immune-mediated encephalitis are limited, but small series describe
either no leucocyte infiltration or scanty lymphocytes without neutrophils, and in a subset
cytotoxic T lymphocytes may predominate [16,36–38]. Similar observations have been made
in rodent models [37].
Our study suggests that MPO in the CSF could be explored as a biomarker for a potential
infectious aetiology in patients with encephalitis. Also serumMPO was also associated with an
infective aetiology so may represent a potential biomarker and both require validation in pro-
spective studies. For example interesting developments have been made in point-of-care tests
for protein biomarkers, such as the lateral flow assays developed for CSF lactate to distinguish
bacterial from viral meningitis [39]. In addition to MPO significant differences were found in
serum for two other mediators between the groups. Interestingly TNFα was identified at higher
concentrations in the immune-mediated than infectious group. Although TNFα has a broad
spectrum of activity, this finding may perhaps reflect the key role it has in promoting the prolif-
eration and differentiation of B cells, which is a pivotal process in the development of autoanti-
bodies [40–43]. ICAM also approached significance, being present at greater concentration in
the infectious than immune-mediated group, potentially as a corollary of greater blood-brain
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barrier permeability as would be expected given the greater pleocytosis that is typically seen in
infectious cases [1, 44–46].
In CSF there were many more differences in the concentrations of mediators between the
aetiological groups. Specifically, higher concentrations of IL-8 were identified in both the infec-
tious and unknown group as opposed to immune-mediated cases, which would be consistent
with the key finding of the role of neutrophils in our study, given the important role of IL-8 in
neutrophil activation [47–49]. In addition, greater concentrations of IL-1RA, IL-4, IL-10 and
IL-1β were found in the immune-mediated group. That both anti-inflammatory (IL-1RA, IL-4
and IL-10) and pro-inflammatory (IL-1β) mediators were elevated in the same aetiological
group support the complex regulatory interaction between these mediators and the importance
of assessing the broad cytokine/chemokine milieu [11].
Interestingly no significant differences were found in the concentration of any of the media-
tors between the infectious and unknown groups in either the serum or the CSF. Only one
other study has assessed profiles between encephalitis aetiologies and identified a higher con-
centration of IFNγ and TNFR1 in 13 patients with HSV than 15 with ‘non-herpetic limbic
encephalitis’ [12]. We did not identify any difference in the relative concentration of interfer-
ons between infectious cases and those of a proven immune-mediated aetiology; although it is
unclear how this relates to the heterogeneous group of ‘non-herpetic limbic encephalitis’ in the
earlier study. That the interferon response, which has been associated with a greater risk of
developing HSV encephalitis, was not found to be significant in our study is a potentially inter-
esting negative, although it may be a consequence of the number of CSF samples available or
the pooling of infectious aetiologies [40,50]. Also some mediators, which have been identified
in previous studies, such as VEGFα, were not detected in significant concentrations in the
majority of patients in this study [51]. Although this may be because previous studies have
focused on pathogens associated with a viraemia and marked blood-brain barrier damage,
rather than primary neurotropic infection, as is seen in HSV, which was the majority of infec-
tious cases in our study [14, 51].
Pooling the patients with different infectious aetiologies together, allowed analysis of factors
which were common between them, and which distinguished them from immune-mediated
encephalitis. It also allowed a comparison with those whose aetiology was unknown., This anal-
ysis makes the assumption that the pathology is similar in infectious cases. Whilst most is
known about HSV infection, which is associated with necrosis, neutrophil invasion, haemor-
rhagic change and secondary autoimmunity in some, fewer histopathological data are available
for other aetiologies [22,52,53]. Indeed focusing on a single infectious cause would have
reduced the numbers of patients, and may have led to us overlooking similarities with those
whose aetiology was unknown. To try to address whether grouping the infectious samples
together, when the majority were due to HSV, had resulted in skewing the results of the infec-
tious group, we looked for differences between the HSV and the other infectious aetiologies.
We found that the concentration of all the mediators assessed in CSF was similar between the
both the HSV and other infectious aetiologies. In serum IL-1α was present at higher concentra-
tions in those with HSV than other infectious aetiologies but IL-1α did not differ significantly
between the infectious group overall and the other aetiologies. Also in serum, ICAM was iden-
tified at lower concentrations in the HSV group than the other infectious aetiologies. This may
be of importance as ICAM was found at a higher concentration in the infectious group overall
than the immune-mediated group and this approached statistical significance. However, for
the majority of mediators in serum and all the mediators in the CSF there were no significance
differences between HSV and the rest of those of an infectious aetiology. This suggests that,
although there are may be histopathological differences between the various infectious cases of
encephalitis, there may be some similarities that support grouping the serum, and particularly
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CSF, host inflammatory response to maximise numbers when making comparisons with pri-
marily immune-mediated cases. Although, this finding may reflect the relatively smaller num-
bers of samples available for this sub-group analysis and further studies are needed to assess
the relative differences between specific pathogens in larger cohorts.
Although the patients for whom no aetiology could be identified had a mediator profile sug-
gestive of infection, they had all undergone an extensive work up for infectious causes, through
the HPA study [2,54]. There could be a number of explanations for failure to identify a patho-
gen. As most diagnoses are now based on CSF PCR for known causes, it may be that the patho-
gen was not present in CSF during the sampling time window, or that the specific pathogen
was not looked for. In this cohort a subsequent analysis reported that there was no significant
difference in the time from admission to first LP between those of known and unknown aetiol-
ogy and also there was no difference between the time to first positive CSF or to first LP
between these groups [54]. However, this did highlight that CSF samples tested for antibody
were more likely to be positive if taken on days 14–28 as opposed to<6days. Indeed, previous
studies have reported that the proportion of CSF positive by PCR is greatest early in admission,
particularly after antiviral treatment [55,56]. Therefore, there may be a critical window for CSF
testing dependent on both the pathogen and the laboratory investigation. Although, pathogen
discovery approaches have identified novel causes of viral encephalitis [28], A subset of CSF
from the HPA study have previously undergone one method of next-generation sequencing
and this did not identify any novel pathogen nucleic acid [54]. It may be that the mediator pro-
file could assist in identifying samples that may be more likely to have an infectious cause to
undergo pathogen discovery. Alternatively the cause may reflect a para- or post-infectious
inflammatory response provoked by peripheral infection, such as with influenza H1N1 [57].
In summary, whilst there were many similarities identified, the cytokine and chemokine
profiles in the CSF of patients with encephalitis of an infectious aetiology differed from those
with an immune-mediated aetiology; those in whom no cause could be identified best reflected
those of an infectious aetiology. MPO may represent a potential biomarker to distinguish
encephalitis due to infection versus immune-mediated causes, which may in part relate to neu-
trophils in the CSF.
Funding and Acknowledgments
BDM is an NIHR Academic Clinical Lecturer and this work received support as part of an
NIHR Doctoral Research Fellowship (NIHR-DRF-2010-03-97). TS received support from the
NIHR Health Protection Research Unit in Emerging and Zoonotic Infections at Liverpool. TS
was also supported by the MRC. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript. This work was supported by the
laboratory team at the Vaccine Evaluation Unit, Public Health England, Manchester, UK. The
views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the
Department of Health or Public Health England. The samples and data from these patients
have been used in associated studies arising from the original Health Protection Agency (now
Public Health England) Aetiological Study of Encephalitis in England.
Supporting Information
S1 Table. Supporting information sera.
(PDF)
S2 Table. Supporting information cerebrospinal fluid.
(PDF)
Cytokine Profiles in Encephalitis of Infectious, Immune-Mediated, and Unknown Cause
PLOS ONE | DOI:10.1371/journal.pone.0146288 January 25, 2016 16 / 19
Author Contributions
Conceived and designed the experiments: BDMMJG JG DB RB TS. Performed the experi-
ments: BDM RB. Analyzed the data: BDMMJG JG DB RB TS. Contributed reagents/materials/
analysis tools: BDMMJG JG DB RB TS. Wrote the paper: BDMMJG JG DB RB NWSD TS.
References
1. Solomon T, Michael BD, Smith PE, Sanderson F, Davies NWS, Hart IJ, et al. Management of sus-
pected viral encephalitis in adults: Association of British Neurologists and British Infection Association
National Guideline. J Infect 2012; 64: 374–373.
2. Granerod J, Ambrose H, Davies NWS, Clewley JP, Walsh AL, Morgan D, et al. Causes of encephalitis
and differences in their clinical presentations in England: a multicentre, population-based prospective
study. Lancet Infect Dis 2010; 10: 835–844 doi: 10.1016/S1473-3099(10)70222-X PMID: 20952256
3. Vincent A, Buckley C, Schott J M, Baker I, Dewar BK, Detert N, et al. Potassium channel antibody-asso-
ciated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain
2004; 127: 701–712. PMID: 14960497
4. Kneen R, Michael BD, Menson E, Mehta B, Easton A, Hemingway C, et al. Management of suspected
viral encephalitis in children- Association of British Neurologists and British Paediatric Allergy Immunol-
ogy and Infection Group National Guidelines. J Infect 2012; 64: 449–477. doi: 10.1016/j.jinf.2011.11.
013 PMID: 22120594
5. Sili U, Kaya A, Mert A, HSV Encephalitis Study Group. Herpes simplex virus encephalitis: Clinical mani-
festations, diagnosis and outcome in 106 adult patients. J Clin Virol 2014; 60:112–118. doi: 10.1016/j.
jcv.2014.03.010 PMID: 24768322
6. Raschilas F, Wolff M, Delatour F, Chaffaut C, De Broucker T, Chevret S, et al. Outcome of and prognos-
tic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin Infect Dis
2002; 35: 254–260. PMID: 12115090
7. Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. N-methyl-D-aspartate antibody
encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-
paraneoplastic disorder of both sexes. Brain 2010; 133: 1655–1667. doi: 10.1093/brain/awq113 PMID:
20511282
8. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience
and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63–
74. doi: 10.1016/S1474-4422(10)70253-2 PMID: 21163445
9. Whitley RJ. Factors indicative of outcome in a comparative trial of acyclovir and vidarabine for biopsy-
proven herpes simplex encephalitis. Infection 1987; 15: S3–8. PMID: 3298070
10. Granerod J, TammCC, Crowcroft NS, Davies NWS, Borchert M, Thomas SL. Challenge of the
unknown: A systematic review of acute encephalitis in non-outbreak situations. Neurology 2010; 75:
924–932. doi: 10.1212/WNL.0b013e3181f11d65 PMID: 20820004
11. Griffiths MJ, Ooi MH, Wong SC, Mohan A, Podin Y, Perera D, et al. In enterovirus 71 encephalitis with
cardio-respiratory compromise, elevated interleukin 1beta, interleukin 1 receptor antagonist, and granu-
locyte colony-stimulating factor levels are markers of poor prognosis. J Infect Dis 2012; 206: 881–892.
doi: 10.1093/infdis/jis446 PMID: 22829643
12. Ichiyama T, Shoji H, Takahashi Y, Matsushige T, Kajimoto M, Inuzuka T, et al. Cerebrospinal fluid lev-
els of cytokines in non-herpetic acute limbic encephalitis: comparison with herpes simplex encephalitis.
Cytokine 2008; 44: 149–153. doi: 10.1016/j.cyto.2008.07.002 PMID: 18722137
13. Kamei S, Taira N, Ishihara M, Sekizawa T, Morita A, Miki K, et al. Prognostic value of cerebrospinal
fluid cytokine changes in herpes simplex virus encephalitis. Cytokine 2009; 46: 187–193. doi: 10.1016/
j.cyto.2009.01.004 PMID: 19261488
14. Winter PM, Dung NM, Loan HT, Kneen R, Wills B, Thu le T, et al Proinflammatory cytokines and che-
mokines in humans with Japanese encephalitis. J Infect Dis 2004; 190: 1618–1626. PMID: 15478067
15. Fraiser C, Papa A, Granjeaud S, Hintzen R, Martina B, Camoin L, et al. Cerebrospinal fluid biomarker
candidates associated with humanWNV neuroinvasive disease. PLoS One 2014; 9: e93637 doi: 10.
1371/journal.pone.0093637 PMID: 24695528
16. Kang X, Li Y, Wei J, Zhang Y, Bian C, Wang K, et al. Elevation of matrix metalloproteinase-9 level in
cerebrospinal fluid of tick-borne encephalitis patients is associated with IgG extravassation and disease
severity. PLoS One 2013; 8: e77427 doi: 10.1371/journal.pone.0077427 PMID: 24223711
17. Michael BD, Elsone L, Griffiths MJ, Faragher B, Borrow R, Solomon T, et al. Post-acute serum eosino-
phil and neutrophil-associated cytokine/chemokine profile can distinguish between patients with
Cytokine Profiles in Encephalitis of Infectious, Immune-Mediated, and Unknown Cause
PLOS ONE | DOI:10.1371/journal.pone.0146288 January 25, 2016 17 / 19
neuromyelitis optica and multiple sclerosis; and identifies potential pathophysiological mechanisms—a
pilot study.Cytokine 2013; 64: 90–96. doi: 10.1016/j.cyto.2013.07.019 PMID: 23941778
18. Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, et al Characteristic cerebro-
spinal fluid cytokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple
sclerosis. PLoS One 2013; 8: e61835 doi: 10.1371/journal.pone.0061835 PMID: 23637915
19. Asaoka K, Shoji H, Nishizaka S, Ayabe M, Abe T, Ohori N, et al. Non-herpetic acute limbic encephalitis:
cerebrospinal fluid cytokines and magnetic resonance imaging findings. Intern Med 2004; 43: 42–48.
PMID: 14964578
20. Schrier RD, Hong S, Crescini M, Ellis R, Perez-Santiago J, Spina C, et al. Cerebrospinal fluid (CSF)
CD8+ T-cells that express interferon-gamma contribute to HIV associated neurocognitive disorders
(HAND). PLoS One 2015: 10: e0116526 doi: 10.1371/journal.pone.0116526 PMID: 25719800
21. Bein CG, Vincent A, Barnett MH, Becker AJ, Blumcke I, Graus F, et al. Immunopathology of autoanti-
body-associated encephalitis: clues for pathogenesis. Brain 2012; 135:1622–38. doi: 10.1093/brain/
aws082 PMID: 22539258
22. Love S, Louis DN, Ellison DW. Greenfield's Neuropathology, Hodder Arnold 2008. ISBN 0340906812:
1293–8.
23. Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ, et al. A randomised phase II
study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005;
76: 1366–1372. PMID: 16170078
24. Burton JM, O’Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of
relapses in multiple sclerosis.Cochrane Database Syst Rev 2012; 12: CD006921. doi: 10.1002/
14651858.CD006921.pub3 PMID: 23235634
25. Szodoray P, Alex P, Chappell-Woodward CM, Madland TM, Knowlton N, Dozmorov I, et al. Circulating
cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system.
Rheumatology 2007; 46:417–25. PMID: 16936328
26. Granerod J, Cousens S, Davies NWS, Crowcroft NS, Thomas SL. New estimates of incidence of
encephalitis in England. Emerg Infect Dis 2013; 19:1455–1462.
27. Irani SR, Gelfand JM, Al-Diwani A, Vincent A. Cell-surface central nervous system autoantibodies: Clin-
ical relevance and emerging paradigms. Ann Neurol 2014; 76:168–84. doi: 10.1002/ana.24200 PMID:
24930434
28. Benjamin LA, Lewthwaite P, Vasanthapuram R, Zhao G, Sharp C, Simmonds P, et al. Human parvovi-
rus 4 as a potential cause of encephalitis in children in India. Emerg Infect Dis 2011; 17: 1484–7 doi:
10.3201/eid1708.110165 PMID: 21801629
29. Ellermann-Eriksen S. Macrophages and cytokines in the early defence against herpes simplex virus.
Virol J 2005; 2: 59. PMID: 16076403
30. Conrady CD, Drevets DA, Carr DJ. Herpes simplex type I infection of the nervous system: is an immune
response a good thing? J Neuroimmunol 2010; 220: 1–9. doi: 10.1016/j.jneuroim.2009.09.013 PMID:
19819030
31. Boutin H, Kimber I, Rothwell NJ, Pinteaux E. The expanding interleukin-1 family and its receptors: do
alternative IL-1 receptor/signaling pathways exist in the brain?Mol Neurobiol 2003; 27: 239–48. PMID:
12845150
32. Metzler KD, Goosmann C, Lubojemska A, Zychlinsky A, Papayannopoulos V. A myeloperoxidase-con-
taining complex regulates neutrophil elastase and actin dynamics during NETosis.Cell Rep 2014; 8:
883–96. doi: 10.1016/j.celrep.2014.06.044 PMID: 25066128
33. Melchjorsen J, Pedersen FS, Mogensen SC, Paludan SR. Herpes simplex virus selectively induces
expression of the CC chemokine RANTES/CCL5 in macrophages through a mechanism dependent on
PKR and ICP0. J Virol 2002; 76: 2780–2788. PMID: 11861845
34. Schachtele SJ, Hu S, Lokensgard JR. Modulation of experimental herpes encephalitis-associated neu-
rotoxicity through sulforaphane treatment. PLoS One 2012; 7: 36216.
35. Vilela MC, Lima G, Rodrigues DH, Lacerda-Queiroz N, Pedroso VS, et al. Absence of CCR5 increases
neutrophil recruitment in severe herpetic encephalitis. BMCNeurosci 2013; 14:19. doi: 10.1186/1471-
2202-14-19 PMID: 23391218
36. Kaluza J, Slowinski J, Bujny T, Grochala M. Paraneoplastic syndrome simulating encephalitis in the
course of testicular seminoma. Folia Neuropathol 1997; 35:24–8. PMID: 9161097
37. Moscato EH, Jain A, Peng X, Hughes EG, Dalmau J, Balice-Gordon RJ. Mechanisms underlying auto-
immune synaptic encephalitis leading to disorders of memory behaviour and cognition: insights from
molecular, cellular and synaptic studies. Eur J Neurosci 2010; 32:298–309 doi: 10.1111/j.1460-9568.
2010.07349.x PMID: 20646055
Cytokine Profiles in Encephalitis of Infectious, Immune-Mediated, and Unknown Cause
PLOS ONE | DOI:10.1371/journal.pone.0146288 January 25, 2016 18 / 19
38. Tuzun E, Zhou L, Baehring JM, Bannykh S, Rosenfeld MR, Dalmau J. Evidence for antibody-mediated
pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol 2009;
118:737–43 doi: 10.1007/s00401-009-0582-4 PMID: 19680671
39. Majwala A, Burke R, Patterson W, Pinkerton R, Muzoora C, Wilson LA, et al. Handheld point-of-care
cerebrospinal fluid lactate testing predicts bacterial meningitis in Uganda. Am J Trop Med Hyg 2013;
88: 127–131 doi: 10.4269/ajtmh.2012.12-0447 PMID: 23243109
40. Kothur K, Wienholt L, Brilot F, Dale RC. CSF cytokines/chemokines as biomarker in neuroinflammatory
CNS disorders: A systematic review. Cytokine 2015; S1043–4666
41. Kimura A, Yoshikura N, Koumura A, Hayasho Y, Inuzuka T. B-cell activating factor belonging to the
tumour necrosis factor family (BAFF) and a proliferation–inducing ligand (APRIL) levels in cerebrospi-
nal fluid of patients with meningoencephalitis. J Neurol Sci 2015; 352:79–83 doi: 10.1016/j.jns.2015.
03.036 PMID: 25847017
42. Leypoldt F, Hoftberger R, Titulaer MJ, Armangue T, Gresa-Arribas N, Jahn H, et al. Investigations on
CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment
response. JAMA Neurol 2015; 72:180–6 doi: 10.1001/jamaneurol.2014.2956 PMID: 25436993
43. Minagawa K, Wakahashi K, Kawano H, Nishikawa S, Fukui C, Kawano Y, et al. Posttranscriptional
modulation of cytokine production in T cells for the regulation of excessive inflammation by TFL. J
Immunol 2014; 192:1512–24 doi: 10.4049/jimmunol.1301619 PMID: 24415781
44. Hsu J, Hoenicka J, Muro S. Targeting, endocytosis and lysosomal delivery of active enzymes to model
human neurons by ICAM-1 targeted nanocarriers. Pharm Res 2015; 32:1264–78 doi: 10.1007/s11095-
014-1531-z PMID: 25319100
45. Liu WY, Wang ZB, Zhang LC, Wei X, Li L. Tight junction in blood-brain barrier: an overview of structure,
regulation, and regulator substances.CNS Neurosci Ther 2012; 18:609–15 doi: 10.1111/j.1755-5949.
2012.00340.x PMID: 22686334
46. Hamd SA, Hamed EA, Abdella MM. Septic encephalopathy: relationship to serum and cerebrospinal
fluid levels of adhesion molecules, lipid peroxidases and SB100.Neuropediatrics 2009; 40: 66–72 doi:
10.1055/s-0029-1231054 PMID: 19809934
47. Zou J, Chen J, Yan Q, Guo Q, Bao C. Serum IL8 and mRNA level of CD11b in circulating neutrophils
are increased in clinically amyopathic dermatomyositis with active interstitial lung disease.Clin Rheu-
matol 2015;
48. Baggiolini M. CXCL8- The first chemokine. Front Immunol 2015; 8:285
49. Kaunisto A, Henry WS, Montaser-Kouhsari L, Jaminet SC, Oh EY, Zhao L, et al. NFAT1 promotes intra-
tumoral neutrophil infiltration by regulating LP8 expression in breast cancer.Mol Oncol 2015; 9:1140–
54 doi: 10.1016/j.molonc.2015.02.004 PMID: 25735562
50. McGlasson S, July A, Jackson A, Hunt D. Type I interferon dysregulation and neurological disease. Nat
Rev Neurol 2015; 11:515–23 doi: 10.1038/nrneurol.2015.143 PMID: 26303851
51. Palus M, Formanová P, Salát J, Žampachová E, Elsterová J, Ružek D. Analysis of serum levels of cyto-
kines, chemokines, growth factors and monoamine neurotransmitters in patients with tick-borne
encephalitis: Identification of novel inflammatory markers with implications for pathogenesis. J Med
Virol 2015; 87: 885–892 doi: 10.1002/jmv.24140 PMID: 25675945
52. Armangue T, Moris G, Cantarin-Extremera V, Conde CE, Rostasy K, Erro ME, et al. Spanish Prospec-
tive Mulitcentre Study of Autoimmunity in Herpes Simplex Encephalitis. Neurology 2015; 85:1736–43
53. Schachtele SJ, Hu S, Lokensgard JR. Modulation of experimental herpes encephalitis-associated neu-
rotoxicity through sulforaphane treatment. PLoS One 2012; 7:e36216 doi: 10.1371/journal.pone.
0036216 PMID: 22558388
54. Ambrose HE, Granerod J, Clewley JP, Davies NW, Keir G, Cunningham R, et al. Diagnostic strategy
used to establish etiologies of encephalitis in a prospective cohort of patients in England. J Clin Micro-
biol 2011; 49:3576 doi: 10.1128/JCM.00862-11 PMID: 21865429
55. Davies NWS, Brown LJ, Gonde J, Irish D, Robinson R, Swan AV, et al. Factors influencing PCR detec-
tion of viruses in cerebrospinal fluid of patients with suspected CNS infections. J Neurol Neurosurg
Psych 2005; 76:82–87
56. Kamei S, Takasu T, Morishima T, Mizutani T. Serial changes of intrathecal viral loads evaluated by
chemiluminescence assay and nested PCR with aciclovir treatment in herpes simplex virus encephali-
tis. Intern Med 2004; 9: 796–801
57. Goenka A, Michael BD, Ledger E, Hart IJ, Absoud M, Chow G, et al. Neurological manifestations of
influenza in adults and children: Results of a national British surveillance study.Clin Infect Dis 2014;
58:775–84 doi: 10.1093/cid/cit922 PMID: 24352349
Cytokine Profiles in Encephalitis of Infectious, Immune-Mediated, and Unknown Cause
PLOS ONE | DOI:10.1371/journal.pone.0146288 January 25, 2016 19 / 19
